NCT05498272View on ClinicalTrials.gov

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Prostate CancerBRCA1 MutationBRCA2 MutationProstatic AdenocarcinomaHigh-Risk Cancer
Interventions
DRUG

Olaparib

300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles)

DRUG

LHRH agonist

Total duration of therapy will be for 180 days with use of agent as per institutional standards

Trial Locations (6)

10032

RECRUITING

Columbia University Irving Medical Center, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

19104

RECRUITING

Penn Medicine Abramson Cancer Center, Philadelphia

21287

RECRUITING

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

45229

RECRUITING

University of Cincinnati, Cincinnati

92093

RECRUITING

University of California San Diego - Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

University of California, San Diego

OTHER

lead

Rana McKay, MD

OTHER